Wedbush Reaffirms Outperform Rating for Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report)'s stock had its "outperform" rating reaffirmed by investment analysts at Wedbush in a note issued to investors on Friday,RTT News reports. They presently have a $4.00 price objective on the stock, down from their prior price objective of $7.00. Wedbush's price target would suggest a potential upside of 455.56% from the stock's current price.

Separately, Citigroup began coverage on Mersana Therapeutics in a report on Friday, November 15th. They set a "buy" rating and a $5.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $5.57.

Mersana Therapeutics Trading Down 44.6 %

MRSN traded down $0.58 during trading on Friday, reaching $0.72. The company had a trading volume of 59,861,995 shares, compared to its average volume of 11,380,588. The company has a debt-to-equity ratio of 13.35, a quick ratio of 2.35 and a current ratio of 2.35. Mersana Therapeutics has a 12-month low of $0.69 and a 12-month high of $6.28. The company has a market cap of $88.94 million, a price-to-earnings ratio of -1.18 and a beta of 1.43. The firm's 50-day simple moving average is $2.00 and its 200 day simple moving average is $1.89.

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last released its quarterly earnings results on Wednesday, November 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.08. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The business had revenue of $12.60 million for the quarter, compared to analyst estimates of $7.53 million. During the same quarter in the previous year, the business earned ($0.35) earnings per share. The firm's revenue was up 63.6% compared to the same quarter last year. Equities research analysts anticipate that Mersana Therapeutics will post -0.61 earnings per share for the current year.

Hedge Funds Weigh In On Mersana Therapeutics

A number of hedge funds have recently added to or reduced their stakes in MRSN. JPMorgan Chase & Co. grew its position in Mersana Therapeutics by 18.9% in the third quarter. JPMorgan Chase & Co. now owns 2,351,359 shares of the company's stock worth $4,444,000 after acquiring an additional 374,460 shares in the last quarter. Exome Asset Management LLC acquired a new stake in shares of Mersana Therapeutics in the 3rd quarter valued at $2,227,000. Barclays PLC boosted its holdings in Mersana Therapeutics by 32.7% in the third quarter. Barclays PLC now owns 494,516 shares of the company's stock worth $934,000 after purchasing an additional 121,799 shares in the last quarter. XTX Topco Ltd increased its position in Mersana Therapeutics by 186.0% during the third quarter. XTX Topco Ltd now owns 347,255 shares of the company's stock worth $656,000 after buying an additional 225,823 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in Mersana Therapeutics by 16.0% during the third quarter. Wellington Management Group LLP now owns 618,305 shares of the company's stock valued at $1,169,000 after buying an additional 85,439 shares in the last quarter. Institutional investors and hedge funds own 93.92% of the company's stock.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.